The effect of alpha-lipoic acid on migraine.

Phase 3

Conditions: migraine.
Migraine without aura
G43.0

Registration Number: IRCT20161203031212N3

Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: Female

Target Recruitment: 90

Inclusion Criteria

Willingness to participation in the study.
Diagnosis of migraine by a neurologist based on ICHD-3 criteria.
Age 20 to 50 years.
Non-menopausal women.

Exclusion Criteria

History of any allergies, intolerances or adverse drug reactions to the supplement.
Pregnancy and lactation.
History of intestinal bypass.
Follow a special diet for the past 6 months.
Smoking or alcohol.
Take any supplements.
Cardiovascular disease, diabetes, liver, kidney, thyroid, malignant disease and other neurological disorders are diagnosed based on the patient interview.
Start taking the new drug within the last 1 month

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Migraine severity. Timepoint: At baseline and after 3 month. Method of measurement: Visual analogue scale.;Migraine frequency . Timepoint: At baseline and after 3 month. Method of measurement: Clinical examination.;Migraine duration. Timepoint: At baseline and after 3 month. Method of measurement: Clinical examination.;Headache impact test. Timepoint: At baseline and after 3 month. Method of measurement: HIT questionnaire.;C-reactive protein (CRP). Timepoint: At baseline and after 3 month. Method of measurement: Colorimetric method.;Serum glutathion. Timepoint: At baseline and after 3 month. Method of measurement: Colorimetric method.;Total antioxidant capacity. Timepoint: At baseline and after 3 month. Method of measurement: Colorimetric method.;Total oxidant capacity. Timepoint: At baseline and after 3 month. Method of measurement: Colorimetric method.;Malondialdehyde. Timepoint: At baseline and after 3 month. Method of measurement: Colorimetric method.

Secondary Outcome Measures

Name	Time	Method
Vascular cell adhesion molecule-1. Timepoint: At baseline and after 3 month. Method of measurement: It will be measured by ELISA kit.;Serum lactate. Timepoint: At baseline and after 3 month. Method of measurement: Colorimetric method.;Serum Nitric Oxide. Timepoint: At baseline and after 3 month. Method of measurement: Colorimetric method.;Depression. Timepoint: At baseline and after 3 month. Method of measurement: DASS questionnaire.;Anxiety. Timepoint: At baseline and after 3 month. Method of measurement: DASS questionnaire.;Stress. Timepoint: At baseline and after 3 month. Method of measurement: DASS questionnaire.